Effects of Xuezhikang (血脂康) and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension

Li Lu; Jian-zhong Zhou; Li Wang; Tie-xu Zhang

doi:10.1007/s11655-009-0266-x

Your Location：

Home >

Browse articles >

Effects of Xuezhikang (血脂康) and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension

Updated：2021-08-27

- Effects of Xuezhikang (血脂康) and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension
- Chinese Journal of Integrative Medicine Vol. 15, Issue 4, Pages: 266-271(2009)
- Affiliations：
  
  1. The First Affiliated Hospital of Chongqing Medical University,Chongqing,China
  2. The First People’s Hospital of Jiulongpo District,Chongqing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-009-0266-x
  CLC：
- Published：2009，
  
  Published Online：18 August 2009，
Scan for full text
Lu, L., Zhou, Jz., Wang, L. et al. Effects of Xuezhikang (血脂康) and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension., Chin. J. Integr. Med. 15, 266 (2009). https://doi.org/10.1007/s11655-009-0266-x

Li Lu, Jian-zhong Zhou, Li Wang, et al. Effects of Xuezhikang (血脂康) and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension. [J]. Chinese Journal of Integrative Medicine 15(4):266-271(2009)
Lu, L., Zhou, Jz., Wang, L. et al. Effects of Xuezhikang (血脂康) and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension., Chin. J. Integr. Med. 15, 266 (2009). https://doi.org/10.1007/s11655-009-0266-x DOI：

Li Lu, Jian-zhong Zhou, Li Wang, et al. Effects of Xuezhikang (血脂康) and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension. [J]. Chinese Journal of Integrative Medicine 15(4):266-271(2009) DOI： 10.1007/s11655-009-0266-x.

摘要

To investigate the impacts of Xuezhikang (血脂康

XZK) or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells (CEPCs) in essential hypertensive (EH) patients. Eighty-eight EH patients were enrolled into the study and randomly assigned to the antihypertensive drug treatment group (ATH group

29 cases)

the pravastatin treatment group (PRA group

29 cases) and the Xuezhikang treatment group (XZK group

30 cases). Patients in the 3 groups were treated with routine antihypertensive drugs. In addition

pravastatin and Xuezhikang were given to the patients in the PRA group and XZK group

respectively. After an eight-week treatment

CEPCs were counted using a laser scanning confocal microscope

and their proliferation function was evaluated by the MTT colorimetric assay and the adherent cell number was counted to estimate the adhesion function. After the treatment

CEPCs in the PRA group (116.60±5.70) and XZK group (114.40±6.55) was significantly higher than that in the ATH group (88.00±6.32

P<0.01). CEPCs proliferation capability and the adhesion function in the PRA group (0.406±0.016

33.60±4.26) and XZK group (0.415±0.018

34.30±3.77) were obviously superior to those in the ATH group (0.333±0.021

P<0.01; 23.30±3.19

P<0.01). No significant difference was found between the pravastatin group and the XZK group. Combined use of XZK or pravastatin with the anti-hypertensive therapy could increase the CEPCs number and improve their function in EH patients with the blood pressure controlled by antihypertensive drugs

leading to benefits independent of pressure-lowering effects.

Abstract

To investigate the impacts of Xuezhikang (血脂康

29 cases)

the pravastatin treatment group (PRA group

29 cases) and the Xuezhikang treatment group (XZK group

30 cases). Patients in the 3 groups were treated with routine antihypertensive drugs. In addition

pravastatin and Xuezhikang were given to the patients in the PRA group and XZK group

respectively. After an eight-week treatment

CEPCs were counted using a laser scanning confocal microscope

and their proliferation function was evaluated by the MTT colorimetric assay and the adherent cell number was counted to estimate the adhesion function. After the treatment

CEPCs in the PRA group (116.60±5.70) and XZK group (114.40±6.55) was significantly higher than that in the ATH group (88.00±6.32

P<0.01). CEPCs proliferation capability and the adhesion function in the PRA group (0.406±0.016

33.60±4.26) and XZK group (0.415±0.018

34.30±3.77) were obviously superior to those in the ATH group (0.333±0.021

P<0.01; 23.30±3.19

leading to benefits independent of pressure-lowering effects.

关键词

Essential Hypertensionendothelial progenitor cellpravastatinXuezhikang

Keywords

Essential Hypertensionendothelial progenitor cellpravastatinXuezhikang

references

Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999–1007.

Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111:2981–2987.

Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) Increase endothelial progenitor cells via the PI 3-kinase Akt pathway. J Clin Invest 2001;108:391–397.

Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rössig L, et al. HMG-CoA reducase inhibitors reduce senescence and increase proliferation of endothelial progenitors via regulation of cell cycle regulatory gene. Circ Res 2003;92:1049–1055.

Guideline Subcommittee. 1999 World Health Organization-international Society of Hypertension. Guidlines for the management of hypertension of Hypertension. J Hypertens 1999;17:151–183.

Yao EH, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007;30:1119–1128.

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.

Gulati R, Jevremovic D, Peterson TE, Witt TA, Kleppe LS, Mueske CS, et al. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation 2003;108:1520–1526.

Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005;23:1831–1837.

Lu L, Zhou JZ, Zhang TX, Wang Z, Hang LW. Influence of essential hypertension on circulating endothelial progenitor cells. Chin Gener Pract (Chin) 2008;11: 744–746.

Rupp S, Badorff C, Koyanagi M, Urbich C, Fichtlscherer S, Aicher A, et al. Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. Basic Res Cardiol 2004;99:61–68.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Third report of the national cholesterol education program (NECP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults final report. Circulation 2002;1063:3143–3146.

Matsubara K, Yamamoto Y, Sonoyama K, Igawa G, Furuse M, Yatsuhashi T, et al. Current status of lipid management of hypertensive patients. Hypertens Res 2003;26:699–704.

Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885–2890.

Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004;110:915–920.

FULL TEXT LINK

More>

Views

341

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effect of chinese herbal medicine for calming Gan (肝) and suppressing hyperactive yang on arterial elasticity function and circadian rhythm of blood pressure in patients with essential hypertension

Study on insulin resistance and genetic polymorphisms in essential hypertension patients of two different kinds of TCM constitution

Clinical observation on Breviscapine in treating hypertension patients complicated with micro-albuminuria of renal impairment

Clinical study on zhenjian granule in improving essential hypertension and insulin resistance

Effect of theo-polyphenols on oxygen free radicals and hemorheology in patients with essential hypertension

Related Author

No data

Related Institution

Institute of Integrated Traditional and Western Medicine, Xiangya Hospital, Central South University

Department of Pathology, The People’s Hospital of Xiangxi Autonomous Region, Jishou

Institute of Hypertensive Disease, Xiangya Hospital, Central South University

Department of Cardiopathy, The Second People’s Hospital of Hunan Province

Department of Echocardiography, The Third Xiangya Hospital, Central South University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰